Search

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023

On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

EHA Issues Recommendations on Mild to Moderate Bleeding Disorders

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems

For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…

Read more